Business Wire

Andy Serkis to Receive IBC’s Highest Award

30.7.2019 18:02:00 EEST | Business Wire | Press release

Share

The IBC2019 International Honour for Excellence will go to Andy Serkis, the director, producer and actor who is today best known for his performance capture roles. These include Gollum, Supreme Leader Snoke, King Kong and Caesar in the Planet of the Apes series. Serkis will accept the award at the climax of the IBC2019 Awards Ceremony, on Sunday night.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005738/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Andy Serkis (Photo: Business Wire)

“IBC is where the technology, the craft and the business of the media industry come together,” said Michael Crimp, CEO of IBC. “The International Honour for Excellence has a long history of rewarding those who have transformed our creative vision. Andy Serkis has achieved this by bringing extraordinary humanity to computer-generated characters.”

Serkis was born in England in 1964 and wanted to be an artist before becoming an actor, working in the theatre and on television. Today he is also a producer and director, with his London-based company Imaginarium Studios producing last year’s Mowgli, Legend of the Jungle, a new interpretation of Kipling’s originals adapted by Serkis, which also featured him co-starring as Baloo the bear alongside Christian Bale’s Bagheera.

His greatest achievement, though, is in making the shift from mere motion capture for CGI towards a combination of technology and the interpretive skill of the actor to create the fidelity of the performance in every detail. This is what gives the performance genuine humanity: his performance as Caesar in the three Planet of the Apes films won him an acting nomination from the Broadcast Film Critics Association.

For bringing together the highest performance standards with the latest in image recognition and CGI technology, the IBC2019 International Honour for Excellence will be presented to Andy Serkis.

“I feel incredibly honoured to have been chosen as the recipient of this year’s prestigious IBC award,” said Andy Serkis. “In turn, I must share this appreciation with the phenomenal legions of creative artists, visionaries and pioneers with whom I’ve been lucky enough to dance with on this journey of next generation storytelling.”

The IBC2019 Awards Ceremony is free to all IBC visitors. It takes place on Sunday evening 15 September at 18.30 in the RAI Auditorium, and will also see the presentation of two new awards this year, honouring achievements in social responsibility and a Young Pioneer, alongside the IBC Innovation Awards.

Earlier on Sunday Andy Serkis will feature in an IBC2019 Conference Convention Keynote , in conversation with Hollywood journalist Carolyn Giardina. They will review his career, the state of the art in motion capture, and discuss where he sees the future of technology in film and television. The Convention Keynote is at 12.30 in the Forum, and is free to attend.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aimee Moore
amoore@ibc.org
+44 (0) 20 7832 4104

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release

Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release

The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye